Abstract 60P
Background
The PI3K/AKT/mTOR pathway plays a major role in melanoma pathogenesis and is also involved in resistance to targeted therapies (TT). The mTORC2 complex plays an important role in this pathway allowing activation of AKT and contributes to the development of BRAF-mutated (BRAFm) melanomas and their resistance to treatments. Once activated, AKT phosphorylates several effector proteins, thus regulating multiple key cellular processes, including proliferation, survival, motility, metabolism and angiogenesis.The goal of our project is to study this complex in melanoma in order to target it specifically. For this purpose, we are focusing more particularly on one principal protein of this complex: SIN1 (also called MAPKAP1) involved in the stabilizing of mTORC2 complex, in its substrate’s specificity, and a major player in the total activation of AKT.
Methods
We are analysing SIN1 expression, by quantitative RT-PCR and IHC and its interaction with other proteins, by Proximity Ligation Assay (PLA), in situ in melanoma biopsies of the French national MELBASE cohort. We will correlate these results with clinico-biological data from MELBASE to determine if there is a diagnostic or prognostic value of these analyses. In a second step, we are mapping the minimal domain of SIN1/NRAS interaction by Peptide Array to develop cell-permeable peptides to inhibit NRAS/mTORC2 interaction. Furthermore, we are evaluating whether SIN1 has also functions independent of the mTORC2 complex in melanoma, by searching for other partners of SIN1 by PLA in melanoma lines.
Results
Our preliminary results show that mTORC2 interacts with NRAS in BRAFm melanoma and that inhibiting the NRAS/mTORC2 interaction reduces the proliferation of melanoma cell lines and in particular those resistant to TT. This leads us to develop inhibitors to specifically target resistant melanomas.
Conclusions
The results of this project will provide us a better understanding of the mTORC2 signalling pathway in the development of BRAFm melanoma and its response to TT. Given the lack of a specific mTORC2 inhibitor at this time, SIN1 could be an ideal therapeutic target to aim for mTORC2.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fondation ARC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - Role of EGFR-targeted therapy in the treatment of advanced and metastatic cervical cancers
Presenter: Abhishek Krishna
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Isothermal chemical KRAS denaturation assay for monitoring stability and inhibitors interactions
Presenter: Randa Mahran
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Influence of efflux and uptake transporters on the pharmacokinetics of the SYK inhibitors entospletinib and lanraplenib
Presenter: Nancy Loos
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Targeting allosteric sites on PDK-1 and PLK-1 with bioactive compounds from <italic>Daucus carota</italic> as a potential therapy for triple-negative breast cancer
Presenter: Kayode Raheem
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Molecular testing and treatment of patients with advanced solid tumors harboring an NTRK gene fusion: Interim results of the REALTRK registry
Presenter: Corinne Vannier
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - Investigating CDK4/6 palbociclib resistance mechanisms in MCF7 breast cancer cell line
Presenter: Heloise Beutier
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts
Presenter: Sofija Jovanović Stojanov
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Molecular Tumor Board at the European Institute of Oncology: An early Italian precision oncology experience
Presenter: Edoardo Crimini
Session: Cocktail & Poster Display session
Resources:
Abstract
72P - MDM alterations in patients with advanced or metastatic cancers
Presenter: Iwona Lugowska
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Automated detection of typical and atypical mitotic figures for improving survival prediction in breast cancer
Presenter: Saima Ben Hadj
Session: Cocktail & Poster Display session
Resources:
Abstract